The Wonder Drug We Don't Know How to Use

She sat on the examination table and told me she was afraid of her own hunger.

She was 44, a teacher, with a hemoglobin A1c that had crossed the threshold into diabetes and a body mass index in the range the textbooks call class II obesity. She had tried everything the culture prescribes: the diets, the regimens, the self-reproach. Nothing had held. Now she was in my clinic because she had read about a new class of drugs in a magazine, and she wanted to know if they might work for her.

I told her they might. I wrote the prescription for a GLP-1 receptor agonist. And then I gave her the handout.

The handout was a single page, photocopied into near illegibility, with a list of foods to “limit” and foods to “enjoy.” It said nothing about preserving muscle. It said nothing about the nausea that can accompany the first weeks of titration, the psychological strangeness of a body that no longer signals hunger in a language the brain recognizes, or the biological reckoning that follows if the drug is ever stopped. I gave her the handout because I had nothing else to give. I am a physician in my final year of residency at a major American academic medical center, and in seven years of training I have learned to run a cardiac arrest, manage a ventilator, and reverse septic shock. I have never been taught what to tell a patient about how to eat on Ozempic.

This is not a gap in my education. It is a photograph of the American health care system, and if you look at it long enough, you will see everything.

I. The Inner Theater of Hunger

To understand what is broken, you must first understand what the drug actually does, because the doing is extraordinary. GLP-1 — glucagon-like peptide-1 — is a hormone secreted by L-cells in the distal small intestine. It is not a foreign chemical introduced into the body; it is a native one, amplified. When you eat a meal, GLP-1 signals the pancreas to release insulin. It slows gastric emptying, so you feel full longer. And it travels to the hypothalamus, where it binds to receptors in the arcuate nucleus and modulates the neural circuitry of appetite. The drug does not merely suppress hunger. It alters the conversation between gut and brain, recalibrating a set point that evolution has spent millions of years defending.

The set point is a hypothesis with evidence behind it. The body, the theory holds, has a weight it considers “normal” and defends it with an arsenal of hormonal and metabolic weapons. When you lose weight, ghrelin surges, leptin falls, and the hypothalamus interprets the deficit as an emergency. Hunger intensifies. Metabolism slows. The willpower model of obesity — the one our culture has insisted upon for generations — holds that the problem is a failure of discipline. The set-point model suggests the problem is biology defending its territory. GLP-1 receptor agonists do not break the siege. They negotiate a truce.

This is a genuine revolution in metabolic medicine. Semaglutide, the molecule sold as Ozempic and Wegovy, and tirzepatide, sold as Mounjaro, have produced weight reductions that were once the exclusive province of bariatric surgery. The SUSTAIN and STEP trials, and the SURMOUNT program, have generated data so striking that they have forced a rethinking of obesity as a chronic disease rather than a behavioral failing. These drugs are not appetite suppressants in the old pharmacologic sense — the amphetamine derivatives that burned hot and fast and left wreckage behind. They are biological correctives, restoring a signaling pathway that may be dysregulated in obesity in the first place.

Ask me how any of this works, and I can draw you the molecular cascade. I can trace the pathway from the L-cell to the islet to the hypothalamic nucleus. I can cite the trial data, the hazard ratios, the adverse event profiles. This is what my training has prepared me to do: to know the drug as a biochemical proposition. But my patient did not come to me for a biochemistry lesson. She came because she wanted to know how to live with this drug in her body, and I did not know what to tell her.

II. The Architecture of Neglect

The problem is not that I am a bad doctor, though I may be. The problem is that American medical training is designed to produce experts in rescue and amateurs in prevention, and it is designed this way for reasons that have nothing to do with medicine and everything to do with money.

Residency training in the United States is funded primarily through Medicare’s graduate medical education budget, which disburses roughly $16 billion annually to teaching hospitals. These hospitals use residents as a workforce, and they depend on that workforce to staff the services that generate revenue: intensive care units, inpatient wards, surgical suites. The half-day per week that most internal medicine residents spend in outpatient clinic is not the core of our training; it is an interruption from the core, a gesture toward continuity in a curriculum built on acuity. We learn to manage decompensated heart failure because decompensated heart failure fills beds. We learn to manage diabetic ketoacidosis because D.K.A. requires an I.C.U. We do not learn to manage the dietary and behavioral scaffolding that might have prevented the heart failure or the D.K.A. in the first place, because prevention does not require an I.C.U. Prevention, in the accounting of the American hospital, is not revenue. It is vacancy.

Everyone in medicine knows this irony. Sustainable health care means keeping people out of hospitals. But hospitals do not capture the savings from empty beds. Insurers do, years later, in the form of avoided admissions. The economic logic of the system rewards occupancy, not emptiness, and so that is what the training infrastructure reflects. We are producing doctors who can keep a 90-year-old alive through a night of multiorgan failure but cannot counsel a 40-year-old through the first month of a GLP-1 agonist, because the first skill is reimbursable and the second is not, and the curriculum follows the cash.

This failure is not unique to obesity medicine. The same gap appears in the management of nearly every chronic disease. We learn the pharmacology of hypertension but not the counseling techniques that might help a patient reduce sodium intake. We memorize the mechanism of statins but receive no training in the motivational interviewing that might help a patient adhere to them. Chronic disease management is, at its core, a relational endeavor. It requires time, trust and a set of communication skills that are teachable but rarely taught. Our training treats these skills as soft, secondary, the province of nutritionists and social workers. It reserves its rigor for the physiology of collapse.

GLP-1 receptor agonists have simply made the gap visible, because they sit at the intersection of pharmacology and behavior in a way that few other drugs do. A statin works whether or not a patient understands it. A beta-blocker lowers heart rate regardless of dietary choices. But a GLP-1 agonist, if prescribed without nutritional support, without a plan for muscle preservation, without preparation for the side effects and the psychological adjustments and the eventual possibility of discontinuation, is a drug only half-deployed. The molecule does its work. But the work is incomplete.

III. What the Patient Needs

Let me return to the examination room, because that is where the abstraction becomes a person.

My patient returned three months later. She had lost 18 pounds. Her A1c had fallen from 7.2 to 6.1. By the metrics that populate our quality dashboards, this was a success. But she was also experiencing nausea that made it difficult to eat anything before noon. She had read on an internet forum that she should eat more protein, but she did not know how much, or what kind, or when. She had noticed that her rings were looser but her arms felt weaker, and a friend had told her about something called “Ozempic face” — the loss of subcutaneous fat that can make a person look gaunt. She was thrilled by the number on the scale and terrified by what it might be costing her.

I did my best. I told her to aim for 1.2 to 1.5 grams of protein per kilogram of body weight per day — a target I had looked up the night before because I knew she was coming. I suggested small, frequent meals. I mentioned resistance training. But I was improvising. There is no module in our residency curriculum on nutritional management during pharmacologic weight loss. No attending physician had ever modeled this conversation for me. I was drawing on fragments — a podcast I had heard, a review article I had skimmed, the same internet forums my patient was reading.

Six months later, her insurance changed. The prior authorization lapsed. The drug’s list price exceeded a thousand dollars a month. She stopped taking it, and within eight weeks the hunger returned, not as a gentle signal but as a roar. The set point, unperturbed by the temporary truce the drug had imposed, reasserted itself. She regained the weight. Her A1c climbed back to 7.0. This was not a moral failure. It was homeostasis, doing what homeostasis evolved to do.

I tell this story not because it is unusual but because it is utterly ordinary. It is happening in examination rooms across the country, every day. We have handed patients a breakthrough and then asked them to figure out the rest on their own.

IV. The Repair

What would a repaired system look like? It would require three things, none of them easy but all of them legible.

First, graduate medical education must rebalance its clinical hours so that chronic disease management is not a peripheral interruption but a central, longitudinal pillar of training. Residents should spend a substantial portion of their time in settings where prevention happens, with the same supervision, the same rigor and the same expectation of mastery that we currently reserve for the I.C.U. The skills of outpatient medicine — nutritional counseling, behavioral modification, shared decision-making — are not soft. They are hard, teachable and assessable, and we should treat them as such.

Second, the funding mechanisms that shape residency training must be restructured to reward preventive care. Medicare’s graduate medical education budget is the invisible hand that guides curriculum design. If that budget were conditioned, in part, on training outcomes related to chronic disease management — on demonstrated competence in nutritional counseling or diabetes prevention — the curriculum would change overnight. Hospitals respond to incentives. Right now, the incentives point toward rescue. They can be made to point elsewhere.

Third, we must develop dedicated curricula around the new physiology of weight regulation, so that the physician prescribing a GLP-1 agonist can speak with as much authority about dietary protein distribution and resistance exercise as about incretin signaling. This is not a niche concern. The Centers for Disease Control and Prevention estimates that more than 40 percent of American adults have obesity. The number of patients on GLP-1 agonists is growing exponentially. We are training a generation of physicians who will spend their careers managing patients on these drugs, and we are sending them into that career without the knowledge they need.

The scientific revolution is here. The therapeutic tools have arrived. What has not arrived is the institutional will to deploy them fully. Until medical training treats the prevention of disease with the same seriousness it brings to the treatment of collapse, we will remain what we are today: experts in rescue and amateurs in care. My patient deserved better than a handout. She deserved a physician trained to walk with her through the full complexity of what these drugs demand. The drugs are ready. The question is whether we are.